Tartagni E - Search Results

1

Nutraceuticals for metabolic syndrome management: from laboratory to benchside.

Cicero AF, Tartagni E, Ertek S. Cicero AF, et al. Among authors: tartagni e. Curr Vasc Pharmacol. 2014;12(4):565-71. doi: 10.2174/15701611113119990120. Curr Vasc Pharmacol. 2014. PMID: 23627983 Review.

2

Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers.

Cicero AF, Tartagni E, Ferroni A, De Sando V, Grandi E, Borghi C. Cicero AF, et al. Among authors: tartagni e. J Altern Complement Med. 2013 Jun;19(6):582-7. doi: 10.1089/acm.2011.0624. Epub 2013 Jan 11. J Altern Complement Med. 2013. PMID: 23308361 Clinical Trial.

3

Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.

Cicero AF, Tartagni E, Ertek S. Cicero AF, et al. Among authors: tartagni e. Expert Opin Drug Saf. 2014 Aug;13(8):1023-30. doi: 10.1517/14740338.2014.932348. Epub 2014 Jun 24. Expert Opin Drug Saf. 2014. PMID: 24961142 Review.

4

Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital.

Spighi A, Tartagni E, D'Addato S, Dormi A, Borghi C. Spighi A, et al. Among authors: tartagni e. J Cardiovasc Med (Hagerstown). 2013 Apr;14(4):270-5. doi: 10.2459/JCM.0b013e328355fae8. J Cardiovasc Med (Hagerstown). 2013. PMID: 22728834

5

Antidiabetic properties of berberine: from cellular pharmacology to clinical effects.

Cicero AF, Tartagni E. Cicero AF, et al. Among authors: tartagni e. Hosp Pract (1995). 2012 Apr;40(2):56-63. doi: 10.3810/hp.2012.04.970. Hosp Pract (1995). 2012. PMID: 22615079 Review.

6

Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella heart study.

Cicero AF, Reggi A, Tartagni E, Grandi E, D'Addato S, Borghi C; Brisighella Heart Study. Cicero AF, et al. Among authors: tartagni e. Adv Clin Exp Med. 2013 Jan-Feb;22(1):69-76. Adv Clin Exp Med. 2013. PMID: 23468264 Free article.

7

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.

Cicero AF, Tartagni E, Ertek S. Cicero AF, et al. Among authors: tartagni e. Expert Opin Biol Ther. 2014 Jun;14(6):863-8. doi: 10.1517/14712598.2014.902929. Epub 2014 Mar 24. Expert Opin Biol Ther. 2014. PMID: 24661068 Review.

8

Can peripheral arterial disease be early screened for in a podiatric setting? A preliminary study in a cohort of asymptomatic adults.

Daddato S, Tartagni E, Dormi A, Ballarini G, Macciantelli M, Malagoni AM, Manfredini F, Manfredini R, Borghi C. Daddato S, et al. Among authors: tartagni e. Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1646-50. Eur Rev Med Pharmacol Sci. 2012. PMID: 23161036 Free article.

9

The older patient with hypertension: care and cure.

Borghi C, Tartagni E. Borghi C, et al. Among authors: tartagni e. Ther Adv Chronic Dis. 2012 Sep;3(5):231-6. doi: 10.1177/2040622312452189. Ther Adv Chronic Dis. 2012. PMID: 23342238 Free PMC article.

10

Metformin and its clinical use: new insights for an old drug in clinical practice.

Cicero AF, Tartagni E, Ertek S. Cicero AF, et al. Among authors: tartagni e. Arch Med Sci. 2012 Nov 9;8(5):907-17. doi: 10.5114/aoms.2012.31622. Epub 2012 Nov 7. Arch Med Sci. 2012. PMID: 23185203 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results